Published Online
on July 29, 2002

A more recent version of this article appeared on August 13, 2002

This Article Full Text (PDF) All Versions of this Article: 106/7/854    most recent 01.CIR.0000024113.26985.CCv1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Li, G. Articles by Thompson, J. A. Search for Related Content PubMed Articles by Li, G. Articles by Thompson, J. A. Related Collections Other Vascular biology

Submitted on February 11, 2002
Revised on May 1, 2002
Accepted on May 13, 2002

Fibroblast Growth Factor Receptor-1 Signaling Induces Osteopontin Expression and Vascular Smooth Muscle Cell--Dependent Adventitial Fibroblast Migration In Vitro

Guohong Li MD, PhD^*, Suzanne Oparil MD, Stacey S. Kelpke PhD, Yiu-Fai Chen PhD, and John A. Thompson PhD

From the Departments of Medicine, Vascular Biology and Hypertension Program, and Surgery, Division of Transplantation, University of Alabama at Birmingham, Ala.

^* To whom correspondence should be addressed. E-mail: ghli{at}uab.edu.

Background—Increased expression of osteopontin (OPN), fibroblast growth factors (FGFs), and their type-1 receptor (FGFR-1) is associated with neointima formation and atherosclerosis. This study tested the hypothesis that ligand activation of FGFR-1 stimulates OPN expression in rat aortic smooth muscle cells (RASMCs), explored the signaling pathway involved, and assessed the functional consequences of activating this pathway on adventitial fibroblast (AF) migration in vitro.

Methods and Results—Exogenous FGF-1 stimulated expression of OPN mRNA and protein in RASMCs in vitro in a dose- and time-dependent manner. OPN mRNA induction by FGF-1 was completely inhibited by either actinomycin D or cycloheximide, selective inhibitors of RNA polymerase and protein synthesis, respectively. OPN mRNA induction by FGF-1 was attenuated by PD 166866, a highly selective and potent FGFR-1 tyrosine kinase inhibitor. Addition of either PP2 or PD98059, specific inhibitors of Src and mitogen-activated extracellular signal--regulated kinase (MEK)/mitogen-activated protein (MAP) kinases, respectively, attenuated FGF-1--stimulated OPN mRNA expression. FGF-1 treatment of RASMCs enhanced RASMC-conditioned medium-stimulated AF migration; this effect was inhibited by pretreatment of RASMCs with either PD166866 or PP2. Immunodepletion of OPN from RASMC-conditioned medium inhibited both basal and FGF-1--stimulated AF migration.

Conclusions—This in vitro study provided a first indication that ligand-activated FGFR-1 plays a significant role in upregulation of OPN expression at the transcriptional level via signaling to Src/MEK/MAP kinases in RASMCs and that this pathway is functionally significant in mediating AF migration via stimulation of OPN expression.

Key words: muscle, smooth • signal transduction • receptors, fibroblast growth factor • osteopontin • cells

This article has been cited by other articles:

				O. M. Gutierrez, J. L. Januzzi, T. Isakova, K. Laliberte, K. Smith, G. Collerone, A. Sarwar, U. Hoffmann, E. Coglianese, R. Christenson, et al. Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease Circulation, May 19, 2009; 119(19): 2545 - 2552. [Abstract] [Full Text] [PDF]

				D. Xing, S. Nozell, Y.-F. Chen, F. Hage, and S. Oparil Estrogen and Mechanisms of Vascular Protection Arterioscler Thromb Vasc Biol, March 1, 2009; 29(3): 289 - 295. [Abstract] [Full Text] [PDF]

				P. J. Pagano and M. J. Haurani Vascular Cell Locomotion: Osteopontin, NADPH Oxidase, and Matrix Metalloproteinase-9 Circ. Res., June 23, 2006; 98(12): 1453 - 1455. [Full Text] [PDF]

				K. L. Schwertfeger, W. Xian, A. M. Kaplan, S. H. Burnett, D. A. Cohen, and J. M. Rosen A Critical Role for the Inflammatory Response in a Mouse Model of Preneoplastic Progression Cancer Res., June 1, 2006; 66(11): 5676 - 5685. [Abstract] [Full Text] [PDF]

				T. Ben-Zvi, A. Yayon, A. Gertler, and E. Monsonego-Ornan Suppressors of cytokine signaling (SOCS) 1 and SOCS3 interact with and modulate fibroblast growth factor receptor signaling J. Cell Sci., January 15, 2006; 119(2): 380 - 387. [Abstract] [Full Text] [PDF]

				R. G. Seipelt, C. L. Backer, C. Mavroudis, V. Stellmach, M. Cornwell, I. M. Seipelt, F. A. Schoendube, and S. E. Crawford Local delivery of osteopontin attenuates vascular remodeling by altering matrix metalloproteinase-2 in a rabbit model of aortic injury J. Thorac. Cardiovasc. Surg., August 1, 2005; 130(2): 355 - 362. [Abstract] [Full Text] [PDF]

				P. Li, S. Oparil, W. Feng, and Y.-F. Chen Hypoxia-responsive growth factors upregulate periostin and osteopontin expression via distinct signaling pathways in rat pulmonary arterial smooth muscle cells J Appl Physiol, October 1, 2004; 97(4): 1550 - 1558. [Abstract] [Full Text] [PDF]

				M. El-Tanani, A. Platt-Higgins, P. S. Rudland, and F. C. Campbell Ets Gene PEA3 Cooperates with {beta}-Catenin-Lef-1 and c-Jun in Regulation of Osteopontin Transcription J. Biol. Chem., May 14, 2004; 279(20): 20794 - 20806. [Abstract] [Full Text] [PDF]

				D. Xing, A. Miller, L. Novak, R. Rocha, Y.-F. Chen, and S. Oparil Estradiol and Progestins Differentially Modulate Leukocyte Infiltration After Vascular Injury Circulation, January 20, 2004; 109(2): 234 - 241. [Abstract] [Full Text] [PDF]

				K. W. Freeman, R. D. Gangula, B. E. Welm, M. Ozen, B. A. Foster, J. M. Rosen, M. Ittmann, N. M. Greenberg, and D. M. Spencer Conditional Activation of Fibroblast Growth Factor Receptor (FGFR) 1, but not FGFR2, in Prostate Cancer Cells Leads to Increased Osteopontin Induction, Extracellular Signal-regulated Kinase Activation, and in Vivo Proliferation Cancer Res., October 1, 2003; 63(19): 6237 - 6243. [Abstract] [Full Text] [PDF]

				A. P. Miller, Y.-F. Chen, D. Xing, W. Feng, and S. Oparil Hormone Replacement Therapy and Inflammation: Interactions in Cardiovascular Disease Hypertension, October 1, 2003; 42(4): 657 - 663. [Abstract] [Full Text] [PDF]